VACCINE |
COMPANY/ DEVELOPER |
TYPE OF VACCINE |
STATUS |
MRNA 1273 |
Moderna/National Institute of Allergy and Infectious Diseases (NIAID)/Biomedical Advanced Research and Development Authority (BARDA)/ Lonza/ Catalent/Rovi/ Medidata/ BIOQUAL |
mRNA-based vaccine |
In use in the US, Canada, the EU, the UK, Switzerland, Israel |
BNT162 |
BioNTech/ Pfizer/ Fosun Pharma/ Rentschler Biopharma |
mRNA-based vaccine |
In use by the European Commission, in the US, UK, Canada, Argentina, Mexico, Saudi Arabia, Bahrain |
AZD 1222 (FORMERLY CHADOX1) |
University of Oxford, Oxford Biomedica, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, Catalent, CSL and AstraZeneca/IQVIA |
Non-Replicating Viral Vector |
One of the largest vaccination programs; in use in the UK, EU, Argentina, Brazil, Dominican Republic, El Salvador, India, Mexico, Marocco, Pakistan |
Janssen’s COVID-19 vaccine (AD26.COV2-S) |
Janssen Pharmaceutical Companies/Johnson & Johnson/Beth Israel Deaconess Medical Center/ Emergent Biosolutions/ Catalent/ Biological E/ Grand River Aseptic Manufacturing (GRAM) |
Non-Replicating Viral Vector (alone or with modified vaccinia Ankara (MVA) boost) |
Phase III clinical trial Approved for emergency use in the USA on February 28, 2021. |
GAM-COVID-VAC (SPUTNIK V) |
Gamaleya Research Institute |
Non-Replicating Adenoviral Vector |
In use in Algeria, Argentina, Bolivia, Hungary, Palestine, Paraguay, Serbia, Turkmenistan, UAE, Venezuela; “registered” in Belarus and Russia |
AD5-NCOV |
CanSino Biologics/ Beijing Institute of Biotechnology/ Petrovax |
Non-Replicating Viral Vector (adenovirus type 5 vector) |
In use for “the military” in China |
To be defined |
Wuhan Institute of Biological Products/ Sinopharm |
Inactivated Virus |
Authorized for emergency use in China and the UAE |
CORONAVAC (FORMERLY PICOVACC) |
Sinovac/ Instituto Butantan/ Bio Farma |
Inactivated Virus |
Authorized for emergency use in Brazil, China, Indonesia |
BBIBP-CORV |
Beijing Institute of Biological Products/ Sinopharm |
Inactivated Virus |
In use in Bahrain, China, Pakistan, the UAE |
INO-4800 |
Inovio Pharmaceuticals/ Beijing Advaccine Biotechnology/ VGXI Inc./ Richter-Helm Biologics/ Ology Bioservices/ International Vaccine Institute/ Seoul National University Hospital/ Thermo Fisher Scientific/ Kaneka Eurogenetec |
DNA plasmid vaccine with electroporation |
Phase II/III clinical trial |
NVX-COV2373 |
Novavax/ Emergent Biosolutions/ Praha vaccines/ Biofabri/ Fujifilm Diosynth Biotechnologies/ FDB/ Serum Institute of India/ SK Bioscience/ Takeda Pharmaceutical Company Limited/ AGC Biologics/ Polypeptide Group/ Endo |
Protein subunit (full length recombinant SARS-CoV-2 glycoprotein nanoparticle vaccine adjuvanted with matrix M) |
Phase III clinical trial |